Zobrazeno 1 - 10
of 38
pro vyhledávání: ''
Autor:
Hayahito Nomi, Kazumasa Komura, Takuya Tsujino, Kohei Taniguchi, Naoki Tanda, Hajime Hirano, Tomohito Tanaka, Haruhito Azuma, Taizo Uchimoto, Yuki Yoshikawa, Yuya Fujiwara, Teruo Inamoto, Yudai Nishimoto, Takeshi Tsutsumi, Kenkichi Saito, Kiyoshi Takahara, Tomoaki Takai, Tomohisa Matsunaga, Atsushi Ichihashi, Naokazu Ibuki, Hirofumi Uehara, Koichiro Minami
Publikováno v:
Medical Oncology. 37
This study aimed to assess the clinical value of C-reactive protein-albumin ratio (CAR) at the initiation of first-line treatment for castration-resistant prostate cancer (CRPC). We identified 221 CRPC patients treated with either androgen-signaling
Autor:
Franco Morelli, Emanuele Naglieri, Nicola Calvani, Laura Orlando, Antonio Gnoni, Vincenzo Emanuele Chiuri, Saverio Cinieri, Palma Fedele
Publikováno v:
Medical Oncology. 36
The aim of our study is to investigate the efficacy of metronomic cyclophosphamide plus low dose of corticosteroids in advanced or metastatic castration-resistant prostate cancer (CRPC) before, between, and after standard chemotherapy, such as doceta
Autor:
Toshikazu Tanaka, Kazuaki Yoshikawa, Shingo Hatakeyama, Naoki Fujita, Toshiaki Tanaka, Yusuke Ishibashi, Hayato Yamamoto, Yoshinori Ikehata, Chikara Ohyama, Toshiaki Kawaguchi, Yasuhiro Hashimoto, Naoya Masumori, Hiroshi Kitamura, Sakae Konishi, Takahiro Yoneyama
Publikováno v:
Medical Oncology. 36
We aimed to compare oncological outcomes and safety of axitinib and sunitinib in patients with treatment-naïve metastatic renal cell carcinoma (mRCC). We retrospectively evaluated 169 patients with mRCC who were treated with axitinib or sunitinib as
Autor:
Charlotte Benson, Shane Zaidi, Winston Chew, Alex Lee, Christina Messiou, Andrew J. Hayes, Winette T. A. van der Graaf, Robin L. Jones, Khin Thway, Aisha Miah, Cyril Fisher
Publikováno v:
Medical Oncology, 35, 11, pp. 138
Medical Oncology, 35, 138
Medical Oncology (Northwood, London, England)
Medical Oncology, 35, 138
Medical Oncology (Northwood, London, England)
Contains fulltext : 199989.pdf (Publisher’s version ) (Open Access) BACKGROUND: Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggressive tumour; however, to our knowledge there are no publ
Publikováno v:
Medical Oncology. 35
The CORRECT trial demonstrated survival benefits with regorafenib monotherapy in patients with treatment-refractory, metastatic colorectal cancer (mCRC). However, the trial's stringent eligibility criteria for regorafenib may limit its external valid
Autor:
Takashi Takeshita, Aiko Sueta, Koichi Suyama, Mototsugu Shimokawa, Yutaka Yamamoto, Hirotaka Iwase, Mai Tomiguchi, Mutsuko Yamamoto-Ibusuki
Publikováno v:
Medical Oncology. 35
Lenvatinib, a multi-tyrosine kinase inhibitor, has been proven to be an effective treatment option for patients with iodine-131-refractory thyroid cancer. Many adverse effects of lenvatinib have been reported; thus, dose reduction is common. However,
Autor:
Marjolaine Gauthier-Loiselle, Wendy Y. Cheng, Ravinder Dhawan, Francis Vekeman, Jennifer Sung, Raymond Miao, Mei Sheng Duh, William Oh
Publikováno v:
Medical Oncology (Northwood, London, England)
It is unclear how treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC) affects real-world patient outcomes. We assessed treatment sequences, patient characteristics and overall survival (OS) in post-docetaxel mCRPC patient
Autor:
Toshiki Ito, Yuto Matsushita, Takayuki Sugiyama, Ryota Aki, Atsushi Otsuka, Hideaki Miyake, Daisuke Motoyama, Keita Tamura
Publikováno v:
Medical Oncology. 34
The objective of this study was to retrospectively analyze the oncological outcomes of Japanese patients with metastatic castration-resistant prostate cancer (mCRPC) who received cabazitaxel. This study included a total of 63 consecutive Japanese mCR
Publikováno v:
Medical Oncology. 33
The objective of this study was to analyze the impact of age on clinical outcomes of metastatic renal cell carcinoma (mRCC) patients receiving axitinib. This study included 144 consecutive mRCC patients who received axitinib for at least 12 weeks as
Autor:
Kevin T. Murphy, Hubert Y. Pan, Joshua D. Lawson, Arno J. Mundt, Santosh Kesari, John F. Alksne, Mariel Cornell
Publikováno v:
Medical Oncology. 29:2040-2045
Glioblastoma multiforme (GBM) is the most common primary brain tumor of adults and carries a poor prognosis. This study sought to investigate recurrence patterns of GBM treated with temozolomide-based chemoradiation. Records for 31 patients treated f